Ad
CUR - Neuralstem Stock Trading
About | Neuralstem Inc. (NASDAQ:CUR)
Not available
Quote | Neuralstem Inc. (NASDAQ:CUR)
| Last: | $ |
|---|---|
| Change Percent: | -2.27% |
| Open: | $1.24 |
| Close: | $1.29 |
| High: | $1.29 |
| Low: | $1.20 |
| Volume: | 78,429 |
| Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Neuralstem Inc. (NASDAQ:CUR)
-
2023-12-01 06:01:56 ET Precious metal prices were trading in green on the first day of the month on Friday, with spot gold ( XAUUSD:CUR ) on track for its third consecutive weekly gain amid hopes of interest rate cut by the first half of next year by the U.S. central bank, whic...
-
2023-11-30 15:49:37 ET Summary Gold prices have surged by nearly $200 or 11% in the past three weeks, reaching $2,046. If gold can close above $2,000 by the end of November, it would mark the first monthly closing above this significant threshold. The weekly and daily charts i...
Message Board Posts | Neuralstem Inc. (NASDAQ:CUR)
| Subject | By | Source | When |
|---|---|---|---|
| $SNCA~could be crazy huge,got @1.65 pps | ALERTS100%to10000%GAIN | investorshub | 04/26/2021 1:36:03 PM |
| Yes merger in play here loading up $$$$ | INFINITI | investorshub | 04/05/2021 12:52:06 PM |
| $SNCA is screaming for the top as investors | AlphaStockNews | investorshub | 04/05/2021 10:55:59 AM |
| Whos the idiots that are selling this low | INFINITI | investorshub | 03/31/2021 11:42:44 PM |
| Filing of Certain Prospectuses and Communications in Connection | INFINITI | investorshub | 03/30/2021 11:09:04 AM |
News, Short Squeeze, Breakout and More Instantly...
Ad
-
RADNOR, Pa., March 19, 2021 (GLOBE NEWSWIRE) -- NeuroRx, Inc. announced the first patient in its P2/3 study of inhaled ZYESAMI™ in the treatment of moderate and severe COVID-19 (AVICOVID-2) was dosed at the University of California Irvine. The trial will be conducted at 10-15 clinica...
-
GERMANTOWN, Md. , Sept. 2, 2020 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, today provided the following letter from Dr. Ken Carter , the Company's Executive Chairm...
-
GERMANTOWN, Md. , May 27, 2020 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq:SNCA), a clinical-stage biopharmaceutical company developing novel treatments for various diseases of high unmet medical need, today announced the closing of its previously announced $5 million registered...